Evidence map›Paper›PMID 36366571›Full record

ReviewViruses2022

SARS-CoV-2 at the Human-Animal Interface: Implication for Global Public Health from an African Perspective.

Ebere Roseann Agusi, Valerie Allendorf, Emmanuel Aniebonam Eze, Olayinka Asala, Ismaila Shittu, Klaas Dietze, Frank Busch, Anja Globig, Clement Adebajo Meseko

Abstract readReview
In one paragraph

Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ebere Roseann AgusiNational Veterinary Research Institute, Vom 930001, Nigeria.
Valerie AllendorfInstitute of International Animal Health/One Health, Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany.
Emmanuel Aniebonam EzeDepartment of Microbiology, University of Nigeria Nsukka, Enugu 410001, Nigeria.ORCID 0000-0002-0201-2027
Olayinka AsalaNational Veterinary Research Institute, Vom 930001, Nigeria.
Ismaila ShittuNational Veterinary Research Institute, Vom 930001, Nigeria.ORCID 0000-0002-2977-9578
Klaas DietzeInstitute of International Animal Health/One Health, Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany.ORCID 0000-0002-6138-6707
Frank BuschInstitute of International Animal Health/One Health, Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany.ORCID 0000-0002-5541-4994
Anja GlobigInstitute of International Animal Health/One Health, Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany.
Clement Adebajo MesekoNational Veterinary Research Institute, Vom 930001, Nigeria.ORCID 0000-0001-7003-7528

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has become the most far-reaching public health crisis of modern times. Several efforts are underway to unravel its root cause as well as to proffer adequate preventive or inhibitive measures. Zoonotic spillover of the causative virus from an animal reservoir to the human population is being studied as the most likely event leading to the pandemic. Consequently, it is important to consider viral evolution and the process of spread within zoonotic anthropogenic transmission cycles as a global public health impact. The diverse routes of interspecies transmission of SARS-CoV-2 offer great potential for a future reservoir of pandemic viruses evolving from the current SARS-CoV-2 pandemic circulation. To mitigate possible future infectious disease outbreaks in Africa and elsewhere, there is an urgent need for adequate global surveillance, prevention, and control measures that must include a focus on known and novel emerging zoonotic pathogens through a one health approach. Human immunization efforts should be approached equally through the transfer of cutting-edge technology for vaccine manufacturing throughout the world to ensure global public health and one health.

Indexed as

COVID-19SARS-CoV-2AnimalsHumansPandemicsPublic HealthZoonosesAfricaCOVID-19emerging infectious diseaseone healthSARS-CoV-2zoonosis

Identifiers

PMID36366571
PMCPMC9696393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.